Flipper., quote: "Plus the expanded access group which is about twice the size of the info arm and slightly more inclusive."
In additioan to the 2018 blinded publication, Management has benefited from having these two unblinded data sources to raise their expectations of a successful trial outcome. I'm reminded of Amarin's Reduce-it trial, where we had a prior Japanese trial,"Jelis," to help us correlate expectations for the trials successful outcome.
Market Data 
Markets 
AI
